The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
Items 801–900 of 1,000
Левонович, Ч. А., Tunyan, L. G., Arzumanyan, М. А., Ustyan, T., Ghrmajyan, H., Asatryan, A. A., Iskandaryan, N., Chobanyan, B. G., Barkhudaryan, A., & Balyan, H. (2024) · Research Square · doi:10.21203/rs.3.rs-5268112/v1
Laimoud, M. H., & Raslan, I. R. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i11.665
Hong, D., Hong, M., Kim, O., Shin, H.-Y., Bak, M., Kim, D., Kim, J., Choi, K. H., Kim, E. K., Lee, J. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5002803
Adhyapak, S. M., & Menon, P. G. (2024) · medRxiv · doi:10.1101/2024.10.22.24315954
Safety of sodium-glucose cotransporter-2 inhibitors for heart failure
Manja, V., & Heidenreich, P. A. (2024) · BMJ · doi:10.1136/bmj.q2424
Jurin, I., Hadžibegović, I., Jurin, H., Rudan, D., Pavlović, N., Radić, M., Manola, Š., & Trkulja, V. (2024) · Cardiologia Croatica · doi:10.15836/ccar2024.525
From Climatic Resilience to Vulnerability
Stewart, S. (2024) · Sustainable development goals series · doi:10.1007/978-3-031-73106-8_4
Promoting Resilience—What Does the Science Say?
Stewart, S. (2024) · Sustainable development goals series · doi:10.1007/978-3-031-73106-8_8
Aberle, J., Blüher, M., Laudes, M., Merkel, M., & Sandow, P. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2435-6818
Kulaiets, N. M. (2024) · Ukrainian journal of cardiovascular surgery · doi:10.30702/ujcvs/24.32(04)/k059-4051
A comprehensive review of the efficacy and safety of ertugliflozin
Xu, B., Liu, Y., Zhang, T., He, Z., & Zhou, J. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2457393
The role of SGLT2 inhibitors in protecting cardiovascular health: beyond glycaemic control
Alharbi, S. A., Alsubaiei, A. A., Alkhalifah, A. H., Alshehri, A. A., Alhaggas, S. S., Alhuthli, S. M., Alfaqih, Y. H., Alnajjar, W. Z., Alshaban, G. A., Ahmed, M. S., et al. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20250050
Management kardiovaskulärer Erkrankungen bei Patienten mit Diabetes
Marx, N., Müller‐Wieland, D., Espinola–Klein, C., Halle, M., Birkenhagen, A., Diemert, P., Mahfoud, F., Wienbergen, H., & Schütt, K. S. (2025) · CME · doi:10.1007/s11298-024-4125-z
Falco, L., Lorenzo, E. D., & Masarone, D. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i3.102893
The sodium-glucose cotransporter 2 inhibitors in perioperative and intensive care settings
Fischer, M.-O., & Guinot, P. (2025) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2025.101511
Non-Pharmacological Interventions in Heart Failure: A Narrative Review
de Freitas, I. O. R., Lemos, M. A. G., Peters, A. W. T., Freire, E. C., Golgher, S. A., de Sousa, L. S. B., Issenguel, R. A. D. C., Lazarotto, M. F. K., Taghlebi, N. H., & Francio, B. (2025) · Journal of Medical Science and Evidences. · doi:10.70789/jmse.v2i2.29
Hong, D., Hong, M., Kim, O., Shin, H.-Y., Bak, M., Kim, D., Kim, J., Choi, K. H., Kim, E. K., Lee, J. M., et al. (2025) · Revista Española de Cardiología · doi:10.1016/j.recesp.2025.02.011
The cardiodiabetologist: not just a question of blood glucose levels
Muscente, F., & Caterina, R. D. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf022
Traitement pharmacologique de l’insuffisance cardiaque
Logeart, D. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.03.002
ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function
Iacovoni, A., Navazio, A., Luca, L. D., Gori, M., Corda, M., Milli, M., Iacoviello, M., Lenarda, A. D., Tano, G. D., Marini, M., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf070
齐, 心. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551502
Wolf, P. J. W., Correia, E. B., Neto, J. M. R., Finger, M. A., dos Santos, C. C., Vasconcellos, M. D. O., Bruscky, L. V. R., Murta, A. C. D. S., Francisco, Y. A., Albrecht, F. C., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240676 · Cited by 4
Treatment Progress of Heart Failure with Preserved Ejection Fraction
王, 义. (2025) · Asian Case Reports in Vascular Medicine · doi:10.12677/acrvm.2025.132002
Qin, W., Gao, Y., Zhao, Y., Bian, N., Fan, W., Wang, W., Gao, Y., & Hu, Z. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00172
Saeed, A., Younas, B., Rohan, A., Haider, U., Mukhtar, A., Nazir, M., & Maryam, M. (2025) · Cureus · doi:10.7759/cureus.86368 · Cited by 1
Kanuparthy, M., Harris, D. D., Broadwin, M., Stone, C. R., Hamze, J., Yalamanchili, K., Sabe, S. A., & Sellke, F. W. (2025) · Asian Cardiovascular and Thoracic Annals · doi:10.1177/02184923251352222
Yagishita, A., Jingu, K., Iimura, K., Iijima, A., Amino, M., Ikari, Y., & Yoshioka, K. (2025) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2025.07.020
Patients’ Beliefs about Their Heart Failure Medications: A Cross-Sectional Survey
Dhanoa, T., Boswell, R., & Barry, A. R. (2025) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.3692 · Cited by 2
The synergistic treatment of heart and kidney disease
Mahfoud, F., Götzinger, F., Kramann, R., Marx, N., & Schwenger, V. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0131
Don't stop now: The imperative to maintain SGLT2 inhibitors in older patients with heart failure
Carluccio, E., Fortuni, F., & Ambrosio, G. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133775
Briggs, A. H., Chen, J., Booth, D., Davis, J. A., Angelis, A., Vaduganathan, M., & Jhund, P. S. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0012
Self-citationLes inhibiteurs du cotransporteur sodium-glucose 2 en périopératoire et en soins critiques
Fischer, M.-O., & Guinot, P. (2025) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2025.05.001
Biswas, S. K., Krishnan, E., Srivastava, Y., Jain, M. K., Bodar, Y. P., Singh, M. H., Zaman, B. M. A., Giri, M. K., Das, M. D. K., Ayaanuddin, S. K., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7613283/v1
Cardiovascular-kidney-metabolic-syndrome: a modern view of the problem
Кanorskiy, S. G. (2025) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2025-6-3-6-16
Ji, X.-D., Yan, S., Lu, P., & Ma, L. (2025) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-025-4022-7
Heart Failure With Comorbidities
Li, Y., & Liang, M. (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000172
Protas, N., Kostitska, I. O., Protas, Y., & Lehun, M. (2025) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2025;13(3):812-826
Abdallah, E. M., Kamal, M., Elkhashab, K., Mohamed, M. A., Binsaleh, A. Y., Mohsen, M., & Hussein, R. R. S. (2025) · Pharmaceuticals · doi:10.3390/ph18111663
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Dong, Y. J., Zheng, S., Wang, W., Wang, D., Wang, H., & Xiang, C.-H. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00508-4
Dapagliflozin in acute heart failure: lessons from the DAPA ACT HF–TIMI 68 trial
Skowronski, J. N., Hosseini, K., Bruno, J., Sakata, Y., Nodari, S., Keramida, K., Cedarbaum, E. R., Canonico, M. E., Palazzuoli, A., & Kato, E. T. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10572-5
Communicating robustness and sex-specific benefit of SGLT2 inhibitors in HFpEF and HFmrEF
Li, Q., Hao, H., Yue, X., An, M., & Yun, Y. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106642
Kamieniak, A., & Gieroba, D. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3884
Kindermann, M., & Böhm, M. (2025) · Springer eBooks · doi:10.1007/978-3-662-69938-6_41
Park, S., Jeong, H. E., Lee, H., You, S. C., & Shin, J.-Y. (2024) · Figshare · doi:10.6084/m9.figshare.26607259
Tanaka, A., Imai, T., Toyoda, S., Sugimoto, K., Yoshida, R., Furuta, M., & Node, K. (2023) · Figshare · doi:10.6084/m9.figshare.23639976
Roddick, A., Wonnacott, A., Webb, D. R., Watt, A., Watson, M. A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., Kossi, M. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24439354
Guo, W., Zhao, L., Huang, W., Chen, J., Zhong, T., Yan, S., Hu, W., Zeng, F., Peng, C., & Yan, H. (2024) · Figshare · doi:10.6084/m9.figshare.26700799
Dihoum, A., Brown, A. J., McCrimmon, R. J., Lang, C. C., & Mordi, I. R. (2024) · Figshare · doi:10.6084/m9.figshare.26289208
Marfella, R., Prattichizzo, F., Sardu, C., Rambaldi, P. F., Fumagalli, C., Marfella, L. V., Grotta, R. L., Frigé, C., Pellegrini, V., D’Andrea, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26664109
Nogueira, A. C. C., Barreto, J., Moura, F. A., Luchiari, B., Abuhab, A., Bonilha, I., Nadruz, W., Gaziano, J. M., Gaziano, T. A., de Carvalho, L. S. F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26631928
Comprehensive Management Strategies for Cardiovascular–Kidney–Metabolic Syndrome
Ouatu, A., & Buliga-Finiș, O. N. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_18
Special Issue: “Recent Advances in Hypertension, Hypercholesterolemia and Type 2 Diabetes”
Bulum, T. (2026) · Biomedicines · doi:10.3390/biomedicines14010098 · Cited by 1
Gautier, P., Lafaurie, M., Bouisset, F., Delmas, C., Cherbi, M., Lhermusier, T., Elbaz, M., & Montastruc, F. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf009
Ho, K. C.-Y., & Mak, L. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.1433
SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy
Sheashaa, H., Ibrahim, R., Pham, H. N., Awad, K., Scalia, I. G., Farina, J., Tamarappoo, B. K., Holloway, C. J., Arsanjani, R., & Ayoub, C. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100722
Wald, R. M., Pravda, N. S., Grewal, J., Roche, S. L., Alonso-González, R., Udell, J. A., Silversides, C. K., Teoh, H., Quan, A., Mazer, C. D., et al. (2026) · medRxiv · doi:10.64898/2026.01.14.26344158
Chanchanayothin, T., Klomwong, C., Saisri, T., Panudom, S., Chaiyamahapurk, S., Theerasuwipakorn, N., Siranart, N., Pajareya, P., Songsirisuk, N., Pravarnpat, C., et al. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101873
Chen, L., Wang, Q., Shen, M., Li, M., Zhu, Y., Zheng, C., Ma, S., Lin, H., Fu, X., Zhang, R., et al. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70090
Bellis, M. D., Imbrici, P., Lenti, R., Liantonio, A., & Luca, A. D. (2026) · Biomedicines · doi:10.3390/biomedicines14010230
Gómez-Huelgas, R., & Perez-Belmonte, L. M. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106735
Firdous, J., Jabeen, F., Zahid, H. F., Hashmi, M. U. H., Mubarika, M., Saeed, M. R., Jabrieh, G., Khalid, E., Hassan, A., Fatima, N. U. A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8683945/v1
Zhang, J., Ling, Y., Li, X., Liu, D., Dong, L., Chen, X., Sun, Y., Shang, Y., & Guo, Y. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505898
El mito de la evidencia clínica: sesgos, heurísticos, falsedades y errores metodológicos
Martín-Fernández, J. (2026) · Revista Clínica de Medicina de Familia · doi:10.55783/rcmf.190106
Tarekegn, G. Y., Kassaw, A. T., Moges, T. A., Wondm, S. A., Dagnew, S. B., Zerihun, T. E., Mussie, D. A., Tamene, F. B., Bekalu, A. F., & Zewdu, W. S. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200607
Baik, M., Jeon, J., Song, T., Yoo, J., & Kim, J. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e91
Dotan, I., Polansky, A., Bergman, I., Ayada, G., Babich, T., Akirov, A., Steinmetz, T., & Diker‐Cohen, T. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.001
Mineralocorticoid Receptor Antagonist and Its Combinations in Heart Failure
Varghese, K., George, J., Khanna, R., Rath, J. K., Sinha, K. K., Dargad, R. R., Gutghe, S., Shah, T., Ganatra, L., Bhatt, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1301
McGuigan, A. (2026) · Drugs & Therapy Perspectives · doi:10.1007/s40267-026-01226-z
Beneficial Effects of Canagliflozin in Heart Failure Associated With Cardiac and Surgical Procedures
Dong, Y., Zhou, F., Chi, L., & Mu, J. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm46719
Mohod, B. A., Mayabhate, M. M., & D., S. A. (2026) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20260247
Cardiovascular and Kidney Effects of Sodium Glucose Cotransporter Inhibitors
Inzucchi, S. E., & Kosiborod, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00012-4
Self-citationMarx-Schütt, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00016-1
DEEDWANIA, P. C., & Banga, A. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.02.049
Hansen, J. L., Tarkia, M., Vasilevska, M., Sandin, P., Asllanaj, E., Wammes, K., Mesterton, J., & Airaksinen, K. E. (2026) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s576426 · Cited by 1
Xue, X., Yu, Z., Dai, M., & Zhang, T. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1790378
Coleman, P., Keenan, B., Monaghan, M., Glass, R., Gardner, S., Fleming, G. F., & Scott, M. G. (2026) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2025-004897
Insuffisance cardiaque : prise en charge périopératoire
Jendoubi, A., Damy, T., & Mongardon, N. (2026) · EMC-Anesthésie réanimation/Encyclopédie médico-chirurgicale. Anesthésie, réanimation · doi:10.1016/s0246-0289(25)45652-7
Zhang, B., Jiang, H., Fang, Z., Zhang, Z., Hu, J., & Zhao, G. (2026) · Cardiology Plus · doi:10.1097/cp9.0000000000000150
Sodium glucose transporter 2 inhibitors for heart failure
Usuda, D., Furukawa, D., Imaizumi, R., Ono, R., Kaneoka, Y., Nakajima, E., Kato, M., Sugawara, Y., Shimizu, R., Inami, T., et al. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i3.118227
Benefits of a comprehensive care model in patients with heart failure and anemia: UMIPIC program
González, J. M. C., Franco, Á. G., Bailón, M. M., Iborra, P. L., Martel, A. C., Pérez-Silvestre, J., Pérez‐Barquero, M. M., & Espinosa, L. M. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502538
Metabolic dysfunction and the use of adjunct medications in type 1 diabetes
Luk, A., Cheah, Y. S., Misra, S., & Salem, V. (2026) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000956
Ambati, S. R., Bhargava Reddy, C., Midthuri, D. J. S., Alavala, L. L., Akumalla, G., Shaik, A. S., & Nishitha Reddy, T. (2026) · Research Square · doi:10.21203/rs.3.rs-9290020/v1
Gallwitz, B., Aberle, J., Birkenfeld, A. L., Kellerer, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M. A., Siegel, E. G., et al. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01469-4
Economic burden associated with systemic inflammation in patients with HFmrEF/HFpEF
Adesoba, T. P., Skaar, J. R., Goss, A., Han, Y., Zhao, X., Ding, Y., Zhou, Y., & Harrington, J. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107439
Yang, Y., Zhou, W., Yang, M., Tang, S. C. W., & Liu, B.-C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1800868
Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults
Toma, L., Buckley, K. D., & Early, N. K. (2026) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2026.78
Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors
Elezaby, A., Nayor, M. G., & Alexander, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00096-0
Dépret, F., Chousterman, B. G., Roger, C., Garnier, M., Lalande, R., Kerforne, T., Rouve, E., Lukaszewicz, A., Ouattara, A., Merdji, H., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-108119
Ignatova, Y. S., Shaputko, D. N., Борзалиевна, П. Т., & Barbarash, O. L. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6464
Nakagawa, A. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag070
盘, 心. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641623
Fioretti, F., Petrie, M. C., Dickert, N. W., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5086
González, J. M. C., Franco, Á. G., Bailón, M. M., Iborra, P. L., Martel, A. C., Pérez-Silvestre, J., Pérez-Barquero, M. M., & Manzano, L. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502538
Beyond survival: nuances in the robustness of SGLT2 inhibitor evidence for HFpEF
Sun, Q., & Yu, L. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106892
Safety of SGLT2 inhibitors for patients with type 2 diabetes: where are we now?
Scheen, A. J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2666186
Taşkan, H., Eşki, S., Eravcı, Ö., İliş, D., & Çakal, S. (2026) · Bulletin of Cardiovasculer Academy · doi:10.4274/kvbulten.galenos.2026.08370
Outpatient drug therapy for children with heart disease in Switzerland: a survey
Bärlocher, J., Good, A. C., Bernardo, S. D., Lava, S. A. G., Stambach, D., Tissot, C., Knirsch, W., Wacker, J., Cavigelli-Brunner, A., Bosch, A., et al. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-07024-z
Zhu, Z., Zhang, Y., Fang, Z., Li, X., Ma, C., Liu, Q., Zhang, Q., Zhu, W., Su, H., & Xu, X. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-03951-y
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
